A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

GLOW (BPC-157 / GHK-Cu / TB-500)
Dermal Luminosity & Multi-Pathway Recovery Matrix

Compound Specifications
GLOW (BPC-157 / GHK-Cu / TB-500)
Dermal Luminosity & Multi-Pathway Recovery Matrix
GLOW is a synergistic triple-peptide formulation uniting BPC-157 (10mg), GHK-Cu (50mg), and TB-500 (10mg/mL) in a 3mL vial. Investigated in research literature for concurrent fibroblast activation, microvascular angiogenesis, and dermal matrix remodeling.
Combines copper-peptide extracellular matrix upregulation (GHK-Cu), angiogenic and tissue cytoprotective signaling (BPC-157), and actin-binding cell motility (TB-500).
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Subcutaneous injection 2-3 times weekly or per clinical protocol.
Frequently Asked Clinical Questions
What makes GLOW different from GHK-Cu alone?
While GHK-Cu focuses on dermal copper remodeling, GLOW adds BPC-157 and TB-500 for enhanced soft-tissue and microvascular cellular support.